Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Anhui
-
Wuhu, Anhui, China, 241001
- The Second Affiliated Hospital of Wannan Medical College
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100005
- Beijing Tongren Hospital, Affiliated to Capital Medical University
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400011
- Chongqing Traditional Chinese Medicine Hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350005
- Fujian Medical University First Affiliated Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510091
- Dermatology Hospital of Southern Medical University
-
Shenzhen, Guangdong, China, 518020
- Shenzhen People's Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, China, 230601
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Luoyang, Henan, China, 450000
- The Second Affiliated Hospital of Henan University of Science and Technology
-
Zhengzhou, Henan, China, 471000
- Henan Provincial People's Hospital
-
-
Hubei
-
Jingzhou, Hubei, China, 434020
- Jingzhou Central Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Xiangya Hospital of Central South University
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215002
- Suzhou Municipal Hospital
-
Zhenjiang, Jiangsu, China, 212001
- Affiliated Hospital of Jiangsu University
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Qilu Hospital of Shandong University
-
Jinan, Shandong, China, 250022
- Shandong Provincial Hospital of Dermatology
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200040
- Huashan Hospital Affiliated to Fudan University
-
Shanghai, Shanghai Municipality, China, 200443
- Shanghai Dermatology Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Chengdu Second People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300120
- Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
-
-
Yunnan
-
Kunming, Yunnan, China, 650000
- The First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- Hangzhou First People's Hospital
-
Hangzhou, Zhejiang, China, 310009
- Hangzhou Third People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF).
-
Male or female subjects aged ≥ 18 years and ≤ 70 years
-
A history of plaque psoriasis for ≥6 months at baseline
-
Meet the following three criteria:
- Psoriasis Area and Severity Index (PASI) score ≥12
- Static Physician's Global Assessment (sPGA) score ≥3
- Psoriasis affected Body Surface Area (BSA) ≥10%
-
The subject requires systemic treatment and/or phototherapy.
Exclusion Criteria:
- Diagnosed with non-plaque psoriasis.
- Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
- Presence of clinically serious, progressive, or uncontrolled disease.
- Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
- Pregnant or lactating women.
- The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ICP-332 Dose A
|
ICP-332 will be administered as tablet for 12 weeks |
|
Experimental: ICP-332 Dose B
|
ICP-332 will be administered as tablet for 12 weeks |
|
Experimental: ICP-332 Dose C
|
ICP-332 will be administered as tablet for 12 weeks |
|
Placebo Comparator: ICP-332 Placebo
|
Placebo will be administered as tablet for 12 weeks |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) at Week 12
Time Frame: Day 1 to Day 85
|
Day 1 to Day 85
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participants With PASI-50, PASI-75, PASI-90, PASI-100 on scheduled Visit(except W12 PASI 75)
Time Frame: Day 1 to Day 85
|
Day 1 to Day 85
|
|
Percentage of Participants at Week12 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate)
Time Frame: Day 1 to Day 85
|
Day 1 to Day 85
|
|
Number of Participants With Adverse Events
Time Frame: Day 1 to Day 113
|
Day 1 to Day 113
|
|
The peak concentration (Cmax)
Time Frame: Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
|
The time to peak (Tmax)
Time Frame: Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
|
The half-life (t1/2)
Time Frame: Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
|
The area under the blood concentration-time curve (AUC0-∞ and AUC0-t)
Time Frame: Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yuling Shi, Shanghai Dermatology Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- ICP-CL-00603
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.